UNSPSC 51151661: Solifenacin

This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8910SQJ1U. European Medicines Agency schedules Solifenacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21589. Solifenacin generally arises in the molecular formula C23H26N2O2. The term SOLIFENACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations schedule solifenacin under HS 29334990 and SITC 51575.

As of Q4 2014, SOLIFENACIN remains the US FDA Preferred Term for this commodity. Solifenacin bears US NLM identifiers UMLS ID C1099677 and NCI Concept Code C75284. SMILES: O(C1C2CCN(C1)CC2)C(=O)N1C(c2c(CC1)cccc2)c1ccccc1.OC(=O)CCC(=O)O.

UNSPSC 51151661 Solifenacin is a Commodity code for a specific pharmaceutical product — an antimuscarinic medication used to treat overactive bladder — yet the recent state and local opportunities tagged under this code do not reflect purchases of solifenacin itself. Instead, the opportunities show state and local health and human services agencies procuring naloxone (an opioid-reversal medication), drug deactivation systems, and pharmacy benefit program services. The mismatch suggests either tagging errors in the underlying procurement data or a code assignment that does not align with actual purchasing activity. State and local governments — specifically county health departments and state health and human services commissions — are the issuing bodies, but the work being solicited is unrelated to solifenacin.

Seminole County, Florida posted an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer pharmacy prescription programs for self-insured employer and state agency benefit plans. Because neither opportunity involves solifenacin procurement, this code shows no actionable recent activity aligned with its stated pharmaceutical scope. Firms evaluating this code should confirm whether the UNSPSC assignment is accurate or whether opportunities involving actual solifenacin purchases exist outside the visible recent posting window.